Shot in the dark here but does anyone know someone who works at Merck/MSD? Need access to a life saving drug that’s currently exorbitantly priced. ...

President Donald Trump on Friday unveiled a sweeping set of drug-pricing agreements with nine major pharmaceutical companies, presenting the initiative as a cornerstone of his effort to bring American medicine costs closer to those paid in Europe.The announcement marked a significant expansion of the administration’s pricing push, with Trump confirming that deals have now been struck with 14 of the 17 drugmakers he formally pressed in July to lower prices. Central to the strategy is the launch of a new dire ...

在此次协议中，最受市场关注的是施贵宝(BMY.US)的让利承诺。该公司表示，将把其畅销抗凝血药 Eliquis免费提供给美国医疗补助(Medicaid)患者。Eliquis是美国处方量最高的药物之一，此举被视为本 轮降价行动中力度最大的措施之一。 特朗普在周五的公开活动上表示，今年7月他致信要求降价的17家大型制药企业中，已有14家同意大幅 下调药价。"这代表着美国医疗体系历史上患者可负担性方面的最大胜利，每一位美国人都将从中受 益。"他同时指出，强生(JNJ.US)、艾伯维公司(ABBV.US)和再生元制药公司(REGN.US)尚未签署协议， 但强生预计"下周就会加入"。 美国总统特朗普推动将美国药价与海外低价市场挂钩之际，多家美国及欧洲大型制药企业近日与白宫达 成协议，同意自愿下调在美销售的药品价格，以换取关税豁免和政策支持。特朗普政府正重启"最惠国 药价"政策，试图通过行政手段压缩美国处方药的高企成本。 智通财经APP获悉，根据白宫披露，已签署协议的企业包括默沙东(MRK.US)、施贵宝(BMY.US)、安进 (AMGN.US)、吉利德科学(GILD.US)、葛兰素史克(GSK.US)、赛诺菲安万特(S ...

The U.S. Food and Drug Administration said on Friday it has granted national priority vouchers to Merck's cholesterol pill and its cancer therapy, making them the latest additions to the fast-track pr... ...

Donald Trump and nine major pharmaceutical companies on Friday announced deals that will slash the prices of their medicines for the government’s Medicaid program and for cash payers, in his latest bid to align US costs with those in other wealthy nations.Bristol Myers Squibb, Gilead Sciences, and Merck and Roche’s US unit Genentech have struck deals. Novartis, Amgen, Boehringer Ingelheim, Sanofi and GSK have also signed on.Under the deals, each drugmaker will cut prices on most drugs sold to the Medicaid p ...

US President Donald Trump on Friday (December 19) announced agreements with nine major pharmaceutical companies to sharply cut the prices of medicines sold through the government’s Medicaid program and to cash-paying consumers, marking his latest push to bring US drug costs in line with those in other wealthy nations.The deals were unveiled at a White House press conference, where Trump appeared alongside senior executives from the participating drugmakers.“We were subsidizing the entire world. We’re not do ...

This year has been one to forget for these pharmaceutical giants.Pfizer (PFE +1.20%) and Merck (MRK +0.71%) are two pharmaceutical giants that have lagged broader equities this year. Both have delivered unimpressive financial results recently, and are facing a somewhat uncertain medium-term outlook as they seek ways to navigate upcoming patent cliffs.Both could make significant progress toward that goal in 2026, but which one is the better option for investors heading into the new year? Let's find out. The ...

RAHWAY, N.J.--(BUSINESS WIRE)--Merck Reaches Agreement With U.S. Government to Expand Access to Medicines and Lower Costs for Americans. ...

Merck & Co. Inc. (NYSE:MRK) will not exercise its option for Evaxion A/S (NASDAQ:EVAX) Gonorrhea vaccine candidate EVX-B2.Gonorrhoea is a common, sexually transmitted infection caused by Neisseria gonorrhoeae.Consequently, Evaxion retains global rights to EVX-B2 and will look for another potential licensing partner.Gonorrhea infects more than 80 million people worldwide each year. Despite decades of research, no vaccine has been approved to date. Preclinical studies demonstrate that EVX-B2 protects against ...

Key Takeaways MRK faces major headwinds as Keytruda, its top revenue driver, nears the loss of exclusivity in 2028.Declining Gardasil sales due to weak China demand and lower vaccine uptake in Japan ail MRK.MRK is counting on Capvaxive, Winrevair and strategic cost savings to help counter patent/pricing headwinds.Merck (MRK) is expected to face some notable headwinds over the next few years that could affect its long-term growth outlook, the most significant being the upcoming loss of exclusivity (“LOE”) fo ...